 Hoth Therapeutics NASDAQ: HOTH stock is rising higher on Monday positive results from a Phase 1 clinical trial of BioLexa. BioLexa is a treatment in development at Hoth Therapeutics for mild-to-moderate atopic dermatitis in adult patients. 